Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis

医学 荟萃分析 心理信息 精神科 重性抑郁障碍 难治性抑郁症 心理干预 抗抑郁药 安慰剂 系统回顾 内科学 随机对照试验 临床试验 梅德林 替代医学 焦虑 心情 法学 病理 政治学
作者
Andrea Cipriani,Toshi A. Furukawa,Georgia Salanti,Anna Chaimani,Lauren Atkinson,Yusuke Ogawa,Stefan Leucht,Henricus G. Ruhé,Erick H. Turner,Julian P. T. Higgins,Matthias Egger,Nozomi Takeshima,Yu Hayasaka,Hissei Imai,Kiyomi Shinohara,Aran Tajika,John P. A. Ioannidis,John Geddes
出处
期刊:The Lancet [Elsevier BV]
卷期号:24 (10128): 1357-1366 被引量:3423
标识
DOI:10.1016/s0140-6736(17)32802-7
摘要

BACKGROUND: Major depressive disorder is one of the most common, burdensome, and costly psychiatric disorders worldwide in adults. Pharmacological and non-pharmacological treatments are available; however, because of inadequate resources, antidepressants are used more frequently than psychological interventions. Prescription of these agents should be informed by the best available evidence. Therefore, we aimed to update and expand our previous work to compare and rank antidepressants for the acute treatment of adults with unipolar major depressive disorder. METHODS: We did a systematic review and network meta-analysis. We searched Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS database, MEDLINE, MEDLINE In-Process, PsycINFO, the websites of regulatory agencies, and international registers for published and unpublished, double-blind, randomised controlled trials from their inception to Jan 8, 2016. We included placebo-controlled and head-to-head trials of 21 antidepressants used for the acute treatment of adults (≥18 years old and of both sexes) with major depressive disorder diagnosed according to standard operationalised criteria. We excluded quasi-randomised trials and trials that were incomplete or included 20% or more of participants with bipolar disorder, psychotic depression, or treatment-resistant depression; or patients with a serious concomitant medical illness. We extracted data following a predefined hierarchy. In network meta-analysis, we used group-level data. We assessed the studies' risk of bias in accordance to the Cochrane Handbook for Systematic Reviews of Interventions, and certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation framework. Primary outcomes were efficacy (response rate) and acceptability (treatment discontinuations due to any cause). We estimated summary odds ratios (ORs) using pairwise and network meta-analysis with random effects. This study is registered with PROSPERO, number CRD42012002291. FINDINGS: We identified 28 552 citations and of these included 522 trials comprising 116 477 participants. In terms of efficacy, all antidepressants were more effective than placebo, with ORs ranging between 2·13 (95% credible interval [CrI] 1·89-2·41) for amitriptyline and 1·37 (1·16-1·63) for reboxetine. For acceptability, only agomelatine (OR 0·84, 95% CrI 0·72-0·97) and fluoxetine (0·88, 0·80-0·96) were associated with fewer dropouts than placebo, whereas clomipramine was worse than placebo (1·30, 1·01-1·68). When all trials were considered, differences in ORs between antidepressants ranged from 1·15 to 1·55 for efficacy and from 0·64 to 0·83 for acceptability, with wide CrIs on most of the comparative analyses. In head-to-head studies, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine were more effective than other antidepressants (range of ORs 1·19-1·96), whereas fluoxetine, fluvoxamine, reboxetine, and trazodone were the least efficacious drugs (0·51-0·84). For acceptability, agomelatine, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine were more tolerable than other antidepressants (range of ORs 0·43-0·77), whereas amitriptyline, clomipramine, duloxetine, fluvoxamine, reboxetine, trazodone, and venlafaxine had the highest dropout rates (1·30-2·32). 46 (9%) of 522 trials were rated as high risk of bias, 380 (73%) trials as moderate, and 96 (18%) as low; and the certainty of evidence was moderate to very low. INTERPRETATION: All antidepressants were more efficacious than placebo in adults with major depressive disorder. Smaller differences between active drugs were found when placebo-controlled trials were included in the analysis, whereas there was more variability in efficacy and acceptability in head-to-head trials. These results should serve evidence-based practice and inform patients, physicians, guideline developers, and policy makers on the relative merits of the different antidepressants. FUNDING: National Institute for Health Research Oxford Health Biomedical Research Centre and the Japan Society for the Promotion of Science.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Engen完成签到,获得积分10
1秒前
李金桥完成签到 ,获得积分10
2秒前
2秒前
很酷的妞子完成签到 ,获得积分10
2秒前
云泪天痕的应助被WGS采纳,获得10
2秒前
kuikui1100完成签到,获得积分10
3秒前
领导范儿的应助被菜鸟学习采纳,获得10
3秒前
莫远阳完成签到,获得积分10
6秒前
无聊的依白完成签到,获得积分10
7秒前
8秒前
完美世界的应助被coco采纳,获得10
8秒前
syvshc的应助被七月流火采纳,获得10
8秒前
科目三的应助被19863737023采纳,获得10
9秒前
xiao端庄完成签到,获得积分10
9秒前
11秒前
11秒前
小张子完成签到,获得积分10
12秒前
1234完成签到,获得积分10
13秒前
13秒前
13秒前
Tong完成签到,获得积分10
14秒前
jiaminzhao完成签到,获得积分10
15秒前
思源的应助被大方的妙梦采纳,获得10
15秒前
15秒前
16秒前
17秒前
落叶发布了新的文献求助10
17秒前
YM发布了新的文献求助10
18秒前
mumu完成签到 ,获得积分10
18秒前
18秒前
Frank发布了新的文献求助10
19秒前
San发布了新的文献求助10
19秒前
英吉利25发布了新的文献求助10
21秒前
仁爱嫣完成签到,获得积分10
21秒前
嘞嘞累哦完成签到,获得积分10
22秒前
ding的应助被陈鸿超采纳,获得10
22秒前
ZRH发布了新的文献求助10
22秒前
jerry完成签到 ,获得积分10
23秒前
斤斤计较发布了新的文献求助10
24秒前
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192871
求助须知:如何正确求助?哪些是违规求助? 9579281
关于积分的说明 21864358
捐赠科研通 7792445
什么是DOI,文献DOI怎么找? 3437059
关于科研通互助平台的介绍 2560639
邀请新用户注册赠送积分活动 2483928